The Dumont & Blake Investment Advisors LLC Continues to Hold Stake in CVS Health Corporation (CVS)

The Dumont & Blake Investment Advisors LLC Continues to Hold Stake in CVS Health Corporation (CVS)

Dumont & Blake Investment Advisors LLC maintained its stake in CVS Health Corporation (NYSE:CVS) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,122 shares of the pharmacy operator’s stock at the end of the second quarter. Dumont & Blake Investment Advisors LLC’s holdings in CVS Health Corporation were worth $1,672,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. State Street Corp increased its stake in CVS Health Corporation by 2.4% in the first quarter. State Street Corp now owns 44,552,112 shares of the pharmacy operator’s stock valued at $4,621,391,000 after buying an additional 1,023,799 shares in the last quarter. Nordea Investment Management AB boosted its position in CVS Health Corporation by 61.3% in the second quarter. Nordea Investment Management AB now owns 11,644,431 shares of the pharmacy operator’s stock valued at $1,114,838,000 after buying an additional 4,423,216 shares during the last quarter. Geode Capital Management LLC boosted its position in CVS Health Corporation by 0.9% in the first quarter. Geode Capital Management LLC now owns 8,917,040 shares of the pharmacy operator’s stock valued at $923,085,000 after buying an additional 77,690 shares during the last quarter. Legal & General Group Plc boosted its position in CVS Health Corporation by 1.9% in the first quarter. Legal & General Group Plc now owns 4,961,136 shares of the pharmacy operator’s stock valued at $514,632,000 after buying an additional 92,196 shares during the last quarter. Finally, Veritas Asset Management LLP boosted its position in CVS Health Corporation by 10.1% in the second quarter. Veritas Asset Management LLP now owns 4,808,477 shares of the pharmacy operator’s stock valued at $460,364,000 after buying an additional 439,848 shares during the last quarter. Institutional investors own 80.89% of the company’s stock.

CVS Health Corporation (NYSE:CVS) traded down 4.39% on Friday, reaching $83.36. The company’s stock had a trading volume of 17,206,730 shares. CVS Health Corporation has a 1-year low of $82.55 and a 1-year high of $106.67. The company has a market capitalization of $88.88 billion, a price-to-earnings ratio of 19.18 and a beta of 0.83. The stock has a 50 day moving average price of $88.40 and a 200-day moving average price of $95.31.

CVS Health Corporation (NYSE:CVS) last posted its quarterly earnings results on Tuesday, August 2nd. The pharmacy operator reported $1.32 EPS for the quarter, beating the consensus estimate of $1.30 by $0.02. CVS Health Corporation had a net margin of 2.88% and a return on equity of 15.86%. The business had revenue of $43.70 billion for the quarter, compared to analysts’ expectations of $44.28 billion. During the same period in the previous year, the company posted $1.19 EPS. CVS Health Corporation’s revenue was up 17.6% on a year-over-year basis. Equities analysts predict that CVS Health Corporation will post $5.85 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, November 3rd. Investors of record on Monday, October 24th will be issued a $0.425 dividend. This represents a $1.70 dividend on an annualized basis and a yield of 2.04%. The ex-dividend date of this dividend is Thursday, October 20th. CVS Health Corporation’s dividend payout ratio is presently 39.08%.

Several research analysts have recently issued reports on the company. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $110.00 price objective (down from $115.00) on shares of CVS Health Corporation in a research report on Tuesday, October 4th. Robert W. Baird lowered their price objective on CVS Health Corporation from $114.00 to $104.00 and set an “outperform” rating for the company in a research report on Monday, October 3rd. Leerink Swann reissued an “outperform” rating and issued a $105.00 target price (down from $110.00) on shares of CVS Health Corporation in a research report on Sunday, October 2nd. Vetr raised CVS Health Corporation from a “buy” rating to a “strong-buy” rating and set a $98.36 target price for the company in a research report on Monday, October 24th. Finally, Jefferies Group reissued a “buy” rating on shares of CVS Health Corporation in a research report on Monday, July 4th. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $112.15.

About CVS Health Corporation

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

Related posts

Leave a Comment